BE2014C009I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C009I2 BE2014C009I2 BE2014C009C BE2014C009C BE2014C009I2 BE 2014C009 I2 BE2014C009 I2 BE 2014C009I2 BE 2014C009 C BE2014C009 C BE 2014C009C BE 2014C009 C BE2014C009 C BE 2014C009C BE 2014C009 I2 BE2014C009 I2 BE 2014C009I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10063435A DE10063435A1 (en) | 2000-12-20 | 2000-12-20 | Chinazoline derivatives, pharmaceuticals containing these compounds, their use and process for their preparation |
| PCT/EP2001/014569 WO2002050043A1 (en) | 2000-12-20 | 2001-12-12 | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C009I2 true BE2014C009I2 (en) | 2021-02-04 |
Family
ID=7667887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C009C BE2014C009I2 (en) | 2000-12-20 | 2014-02-18 |
Country Status (40)
| Country | Link |
|---|---|
| EP (2) | EP1345910B9 (en) |
| JP (1) | JP3827641B2 (en) |
| KR (1) | KR100852102B1 (en) |
| CN (1) | CN1277822C (en) |
| AR (1) | AR040524A1 (en) |
| AT (1) | ATE430136T1 (en) |
| AU (2) | AU1917402A (en) |
| BE (1) | BE2014C009I2 (en) |
| BG (1) | BG66139B1 (en) |
| BR (1) | BRPI0116266B8 (en) |
| CA (1) | CA2432428C (en) |
| CY (2) | CY1109290T1 (en) |
| CZ (1) | CZ302721B6 (en) |
| DE (2) | DE10063435A1 (en) |
| DK (1) | DK1345910T3 (en) |
| EA (1) | EA006317B1 (en) |
| EE (1) | EE05244B1 (en) |
| ES (1) | ES2326617T3 (en) |
| FR (1) | FR14C0009I2 (en) |
| HK (1) | HK1060571A1 (en) |
| HR (1) | HRP20030504B1 (en) |
| HU (2) | HU228874B1 (en) |
| IL (2) | IL156277A0 (en) |
| LT (1) | LTC1345910I2 (en) |
| LU (1) | LU92370I2 (en) |
| ME (1) | ME02777B (en) |
| MX (1) | MXPA03005559A (en) |
| MY (1) | MY136086A (en) |
| NO (2) | NO325672B1 (en) |
| NZ (1) | NZ526918A (en) |
| PL (1) | PL214798B1 (en) |
| PT (1) | PT1345910E (en) |
| RS (1) | RS50860B (en) |
| SI (1) | SI1345910T1 (en) |
| SK (1) | SK287573B6 (en) |
| TW (1) | TWI295992B (en) |
| UA (1) | UA74614C2 (en) |
| UY (1) | UY27078A1 (en) |
| WO (1) | WO2002050043A1 (en) |
| ZA (1) | ZA200304141B (en) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE04748B1 (en) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10204462A1 (en) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US20040044014A1 (en) | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| DE10221018A1 (en) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
| PE20040945A1 (en) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | PREPARATION OF SUBSTITUTED QUINAZOLINES |
| DE10307165A1 (en) * | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10334226A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10349113A1 (en) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Process for the preparation of aminocrotonyl compounds |
| PL1746999T3 (en) * | 2004-05-06 | 2012-07-31 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| WO2006081741A1 (en) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Quinazoline compounds or their medical salts and preparation and medical usage thereof |
| KR100832593B1 (en) * | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | Quinazoline derivatives as an signal trnasduction inhibitor and method for the preparation thereof |
| EP3173084B1 (en) * | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| EP1948180B1 (en) | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
| EP1981863B1 (en) | 2006-01-26 | 2012-10-10 | Boehringer Ingelheim International GmbH | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
| PT2068880E (en) * | 2006-09-18 | 2012-07-12 | Boehringer Ingelheim Int | Method for treating cancer harboring egfr mutations |
| EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
| JP5377332B2 (en) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bicyclic heterocycles, drugs containing these compounds, their use and their preparation |
| BRPI0907916A2 (en) | 2008-02-07 | 2015-07-28 | Boehringer Ingelheim Int | Spirocycle heterocycles, medicaments containing such compounds, and processes for preparing them |
| EP2303276B1 (en) | 2008-05-13 | 2013-11-13 | AstraZeneca AB | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| UY31867A (en) | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | NEW SOLID PHARMACEUTICAL FORMULATIONS THAT INCLUDE BIBW 2992 |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| JP5539351B2 (en) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them |
| WO2010054285A2 (en) * | 2008-11-10 | 2010-05-14 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| EP2387401A1 (en) | 2009-01-14 | 2011-11-23 | Boehringer Ingelheim International GmbH | Method for treating colorectal cancer |
| US20120142703A1 (en) | 2009-05-14 | 2012-06-07 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
| JP2012526767A (en) * | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel combination therapy in the treatment of cancer and fibrotic diseases |
| PT2451445T (en) | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| US20130012465A1 (en) | 2009-12-07 | 2013-01-10 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
| WO2011084796A2 (en) * | 2009-12-21 | 2011-07-14 | Qiang Zhang | Novel quinazoline derivatives |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| SI2608792T1 (en) | 2010-08-26 | 2018-02-28 | Boehringer Ingelheim International Gmbh | Methods of administering an egfr inhibitor |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| SG10201913982WA (en) | 2011-03-04 | 2020-03-30 | Newgen Therapeutics Inc | Alkyne Substituted Quinazoline Compound And Methods Of Use |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| WO2012155339A1 (en) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof |
| CN102838590B (en) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs |
| EP2753616A1 (en) | 2011-10-06 | 2014-07-16 | Ratiopharm GmbH | Crystalline forms of afatinib di-maleate |
| CN103073539B (en) * | 2011-10-26 | 2016-05-11 | 齐鲁制药有限公司 | 4-(substituted benzene amino) quinazoline derivant and preparation method thereof, pharmaceutical composition and purposes |
| EP2805940B1 (en) | 2012-01-17 | 2016-11-23 | Astellas Pharma Inc. | Pyrazine carboxamide compound |
| CN103772380A (en) * | 2012-10-23 | 2014-05-07 | 杨子娇 | Type of compounds for treating narrow chamber angle and use of compounds |
| US20150368230A1 (en) | 2013-02-01 | 2015-12-24 | Boehringer Ingelheim International Gmbh | Radiolabeled quinazoline derivatives |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (en) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Therapeutic uses of empagliflozin |
| CN105377266A (en) | 2013-04-18 | 2016-03-02 | 勃林格殷格翰国际有限公司 | Pharmaceutical composition, methods for treating and uses thereof |
| WO2014180271A1 (en) * | 2013-05-10 | 2014-11-13 | 苏州明锐医药科技有限公司 | Method for preparing afatinib and intermediate thereof |
| CN103254182A (en) * | 2013-05-10 | 2013-08-21 | 苏州明锐医药科技有限公司 | Method for preparing Afatinib |
| CN103254183B (en) * | 2013-05-10 | 2015-11-11 | 苏州明锐医药科技有限公司 | Ah method is for the preparation method of Buddhist nun |
| WO2014183560A1 (en) * | 2013-05-16 | 2014-11-20 | 苏州明锐医药科技有限公司 | Afatinib and preparation method of intermediate thereof |
| CN103242303B (en) * | 2013-05-16 | 2015-03-25 | 苏州明锐医药科技有限公司 | Afatinib preparation method |
| CN104513229A (en) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | Quinazoline derivatives and preparation method thereof |
| CN103755688B (en) * | 2013-12-24 | 2015-11-18 | 江苏奥赛康药业股份有限公司 | A kind of Ah method is for the preparation method of Buddhist nun's compound |
| US9242965B2 (en) * | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| WO2015103456A1 (en) | 2014-01-02 | 2015-07-09 | Teva Pharmaceuticals International Gmbh | Crystalline forms of afatinib di-maleate |
| CN105315263B (en) * | 2014-07-30 | 2018-11-27 | 正大天晴药业集团股份有限公司 | The synthetic method of afatinib intermediate |
| EP3023421A1 (en) | 2014-11-21 | 2016-05-25 | Sandoz Ag | Crystalline forms of afatinib dimaleate |
| CN105801568B (en) | 2015-01-15 | 2019-07-30 | 杭州普晒医药科技有限公司 | One maleate crystal form of Afatinib and preparation method thereof and pharmaceutical composition |
| JP6704422B2 (en) * | 2015-03-20 | 2020-06-03 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドＣｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．，Ｌｔｄ． | Quinazoline derivative salt and method for producing the same |
| CN105175400B (en) * | 2015-09-29 | 2018-04-10 | 河北神威药业有限公司 | A kind of preparation method of afatinib intermediate |
| WO2017141271A1 (en) * | 2016-02-17 | 2017-08-24 | Sun Pharmaceutical Industries Ltd. | Stable pharmaceutical composition of afatinib |
| CN106442793B (en) * | 2016-10-21 | 2019-05-24 | 河北神威药业有限公司 | A kind of detection method of the intermediate for preparing Afatinib and its enantiomter |
| TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
| JP2021506974A (en) * | 2017-12-18 | 2021-02-22 | スターングリーン、インク． | Pyrimidine compounds useful as tyrosine kinase inhibitors |
| CN110437163A (en) * | 2018-05-03 | 2019-11-12 | 斯特恩格林公司 | Pyrimidines as tyrosine kinase inhibitor |
| MX2021003517A (en) | 2018-09-25 | 2021-08-16 | Black Diamond Therapeutics Inc | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use. |
| CN109265449B (en) * | 2018-11-07 | 2021-11-23 | 沈阳工业大学 | EGFR and HER2 double-target tyrosine kinase inhibitor and preparation method and application thereof |
| SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
| CN109824657A (en) * | 2019-03-26 | 2019-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | Two maleic acid Afatinib novel crystal forms of one kind and its preparation method and application |
| CN110590682A (en) * | 2019-10-14 | 2019-12-20 | 重庆医科大学 | Method for preparing afatinib impurity and prepared impurity |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| EP4093394A1 (en) | 2020-01-20 | 2022-11-30 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100503580C (en) * | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | Irreversible inhibitor of tyrosine kinase |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| DE19911366A1 (en) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases |
| US6972288B1 (en) * | 1999-02-27 | 2005-12-06 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| DE19908567A1 (en) * | 1999-02-27 | 2000-08-31 | Boehringer Ingelheim Pharma | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases |
| DE19911509A1 (en) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| EE04748B1 (en) * | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation |
| DE50111799D1 (en) * | 2000-04-08 | 2007-02-15 | Boehringer Ingelheim Pharma | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF |
-
2000
- 2000-12-20 DE DE10063435A patent/DE10063435A1/en not_active Withdrawn
-
2001
- 2001-12-12 PL PL361798A patent/PL214798B1/en unknown
- 2001-12-12 MX MXPA03005559A patent/MXPA03005559A/en active IP Right Grant
- 2001-12-12 EA EA200300671A patent/EA006317B1/en not_active IP Right Cessation
- 2001-12-12 BR BRPI0116266A patent/BRPI0116266B8/en not_active IP Right Cessation
- 2001-12-12 DK DK01271363T patent/DK1345910T3/en active
- 2001-12-12 SI SI200130916T patent/SI1345910T1/en unknown
- 2001-12-12 EP EP01271363.2A patent/EP1345910B9/en not_active Expired - Lifetime
- 2001-12-12 KR KR1020037008246A patent/KR100852102B1/en active Protection Beyond IP Right Term
- 2001-12-12 PT PT01271363T patent/PT1345910E/en unknown
- 2001-12-12 RS YUP-496/03A patent/RS50860B/en unknown
- 2001-12-12 SK SK771-2003A patent/SK287573B6/en not_active IP Right Cessation
- 2001-12-12 JP JP2002551540A patent/JP3827641B2/en not_active Expired - Lifetime
- 2001-12-12 WO PCT/EP2001/014569 patent/WO2002050043A1/en active Application Filing
- 2001-12-12 ME MEP-2008-595A patent/ME02777B/en unknown
- 2001-12-12 ES ES01271363T patent/ES2326617T3/en not_active Expired - Lifetime
- 2001-12-12 EP EP09158964A patent/EP2112140A1/en not_active Withdrawn
- 2001-12-12 CN CNB018208665A patent/CN1277822C/en not_active Expired - Lifetime
- 2001-12-12 CA CA002432428A patent/CA2432428C/en not_active Expired - Lifetime
- 2001-12-12 AU AU1917402A patent/AU1917402A/en active Pending
- 2001-12-12 CZ CZ20031930A patent/CZ302721B6/en not_active IP Right Cessation
- 2001-12-12 UA UA2003076821A patent/UA74614C2/en unknown
- 2001-12-12 IL IL15627701A patent/IL156277A0/en unknown
- 2001-12-12 NZ NZ526918A patent/NZ526918A/en not_active IP Right Cessation
- 2001-12-12 HU HU0301852A patent/HU228874B1/en active Protection Beyond IP Right Term
- 2001-12-12 AT AT01271363T patent/ATE430136T1/en active
- 2001-12-12 DE DE50114874T patent/DE50114874D1/en not_active Expired - Lifetime
- 2001-12-12 AU AU2002219174A patent/AU2002219174B2/en active Active
- 2001-12-12 EE EEP200300300A patent/EE05244B1/en active Protection Beyond IP Right Term
- 2001-12-17 UY UY27078A patent/UY27078A1/en not_active Application Discontinuation
- 2001-12-19 MY MYPI20015767A patent/MY136086A/en unknown
- 2001-12-19 TW TW090131520A patent/TWI295992B/en active
- 2001-12-19 AR AR20010105883A patent/AR040524A1/en active Pending
-
2003
- 2003-05-28 ZA ZA200304141A patent/ZA200304141B/en unknown
- 2003-06-03 IL IL156277A patent/IL156277A/en active Protection Beyond IP Right Term
- 2003-06-16 NO NO20032726A patent/NO325672B1/en active Protection Beyond IP Right Term
- 2003-06-18 HR HR20030504A patent/HRP20030504B1/en not_active IP Right Cessation
- 2003-06-19 BG BG107929A patent/BG66139B1/en active Active
-
2004
- 2004-05-20 HK HK04103590A patent/HK1060571A1/en not_active IP Right Cessation
-
2009
- 2009-07-23 CY CY20091100793T patent/CY1109290T1/en unknown
-
2014
- 2014-01-30 FR FR14C0009C patent/FR14C0009I2/en active Active
- 2014-01-31 LU LU92370C patent/LU92370I2/en unknown
- 2014-02-06 LT LTPA2014005C patent/LTC1345910I2/en unknown
- 2014-02-11 NO NO2014003C patent/NO2014003I2/en not_active IP Right Cessation
- 2014-02-12 CY CY2014008C patent/CY2014008I2/en unknown
- 2014-02-12 HU HUS1400005C patent/HUS1400005I1/en unknown
- 2014-02-18 BE BE2014C009C patent/BE2014C009I2/fr unknown